Short answer
Lantheus Holdings, Inc. (LNTH) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 8.01 (Other Events). Definitive agreement to sell CDMO business and Springfield, New Jersey facility to PharmaLogic.
Lantheus Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Definitive agreement to sell CDMO business and Springfield, New Jersey facility to PharmaLogic
- Sale remains subject to customary closing conditions and potential regulatory approvals
- Transition services required immediately after closing, creating near-term execution obligations
- Long-term supply agreement shifts lutetium Lu 177 dotatate manufacturing to PharmaLogic’s Agilera franchise
- Transaction separates Lantheus from CDMO operations while preserving supply access for a key product
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lantheus Holdings, Inc. 8-K filings
Get the next LNTH 8-K as it lands
Follow LNTH for push alerts, or ask the research agent what this filing means.